Out now in Innovations in Pharmaceutical Technology, Optibrium’s Global Head of Application Science and President of Optibrium Inc, Dr Tamsin Mansley discusses the past, present and future of AI in drug discovery. She shares her thoughts on how AI technologies are best serving the drug discovery industry, how any limitations in the field are being tackled by innovations in technology and where the future of new drug discovery technologies look to be headed.
Introduction
For drug discovery, there are three key areas of chemistry in which artificial intelligence (AI) technologies can be applied: generative chemistry, synthesis planning and compound property prediction. Together, these cover which potential drug candidates could be considered, how to synthesise them, and whether they will have the required balance of properties to successfully meet the project’s objectives.
Want to use AI in your drug discovery projects?
About the author
Tamsin Mansley
Global Head of Application Science and President Optibrium Inc.
More AI in drug discovery resources
Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
Now, watch Matt Segall, PhD, CEO at Optibrium, as he introduces a real world case study where we applied deep learning to guide a project, in which potential compounds were displaying good activity profiles but the team wanted to improve their PK profile to achieve better efficacy.
Integrated AI synthesis prediction in drug discovery
Learn more about how AI, machine learning and other computational tools can support the discovery process, bringing you feasible synthetic routes to your target compounds.
Cerella™: Reduce the time and cost of your discovery cycles with deep learning
In this webinar, we demonstrate how Cerella™ (AI drug discovery software) highlights new opportunities and guides more efficient compound optimisation.
Related content from across the site
7th RSC-BMCS AI in chemistry conference
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
26th North American ISSX and JSSX Meeting
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
Optibrium Appoints James Halle as Chief Commercial Officer
Key appointment brings extensive software commercial experience to drive global growth
